A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a multipart study that consists of a HC-7366 monotherapy cohort, a combination dose escalation, and a combination dose expansion. Approximately 80 patients will be enrolled in this study (up to 20 patients will be enrolled into the HC-7366 monotherapy cohort, up to 30 patients into the combination dose escalation, and up to 30 patients into the combination dose expansion). The primary purpose of this study is to determine the maximum tolerated dose of HC-7366 in combination with belzutifan in patients with locally advanced (inoperable) or metastatic RCC with predominantly clear cell histology, irrespective of VHL gene mutation status.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent ma zdiagnozowanego raka nerki, który jest miejscowo zaawansowany (nie da się go usunąć operacyjnie) lub rozsiany (przerzutowy), z dominującym typem komórek jasnych.
- •Pacjent ma ukończone 18 lat.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (21)
University of Arizona Cancer Center
Tucson, United States
University of California San Diego Moores Cancer Center
La Jolla, United States
Cedars-Sinai Medical Center
Los Angeles, United States
University of Colorado Anschutz Medical Campus
Aurora, United States
Rocky Mountain Cancer Centers, LLP
Lone Tree, United States
Yale - New Haven Hospital
New Haven, United States
Karmanos Cancer Institute
Detroit, United States
HealthPartners Cancer Research Center
Saint Paul, United States
Washington University School of Medicine
St Louis, United States
Memorial Sloan Kettering Cancer Center
New York, United States
University Hospitals Cleveland Medical Center
Cleveland, United States
Cleveland Clinic
Cleveland, United States
Providence Cancer Institute
Portland, United States
Sarah Cannon Research Institute (SCRI)
Nashville, United States
Texas Oncology
Dallas, United States
University of Texas Southwestern Medical Center
Dallas, United States
University Medical Center & Texas Tech Health Science Center
Lubbock, United States
Virginia Cancer Specialists
Fairfax, United States
Swedish Medical Center
Seattle, United States
Fred Hutchinson Cancer Center
Seattle, United States
University of Wisconsin - Carbone Cancer Center
Madison, United States
Trial contact
Michele Gargano
Paulette Mattson
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.